NASDAQ:GLYC - GlycoMimetics, Inc.
$12.11
 $0.14
+1.17%
4:00PM EDT
2019-04-18
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GLYC     avg for
industry  
  avg for
sector  
42 stocks weight:  2. 19   203. 85   241. 91  
42 stocks rank:  3. 25 K 1. 44 K 1. 05 K
# analyst opinions:  6. 00   14. 51   13. 97  
mean recommendation:  1. 70   2. 09   2. 01  

quick ratio:  24. 00   5. 27   1. 81  
current ratio:  24. 22   5. 62   2. 25  

target price low:  19. 00   84. 80   115. 21  
target price avg:  24. 00   111. 51   137. 51  
target price high:  35. 00   135. 81   157. 84  
1-yr high:  19. 19   114. 23   138. 78  
last close:  12. 11   87. 66   116. 69  
50-day avg:  12. 03   95. 54   123. 44  
200-day avg:  12. 82   94. 25   121. 11  
1-yr low:  8. 47   72. 78   98. 34  
volume:  215. 85 K 4. 11 M 8. 07 M
50-day avg volume:  219. 54 K 2. 76 M 5. 02 M
200-day avg volume:  286. 88 K 2. 92 M 4. 59 M

1-day return:  1. 17 % -0. 41 % 0. 07 %
this week return:  0. 75 % -5. 74 % -4. 11 %
12-wk return:  12. 03 % 1. 61 % -0. 05 %
52-wk return:  -32. 45 % 3. 12 % 8. 78 %

enterprise value (EV):  312. 86 M 48. 94 B 114. 64 B
market cap:  522. 78 M 43. 07 B 104. 73 B
EBITDA:  -51. 23 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -6. 11   4. 22   12. 73  
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -48. 27 M 2. 20 B 4. 20 B

shares outstanding:  43. 17 M 571. 70 M 1. 24 B
shares:  33. 47 M 571. 81 M 1. 23 B
shares short:  5. 91 M 10. 17 M 13. 00 M
shares short prior month:  6. 02 M 9. 54 M 17. 33 M
short ratio:  23. 54   5. 41   3. 28  
total cash/share:  4. 86   11. 14   9. 33  
total cash:  209. 92 M 6. 71 B 7. 15 B
free cash flow:  -25. 92 M 3. 58 B 2. 96 B
operating cash flow:  -43. 33 M 4. 15 B 4. 30 B

book value:  4. 76   12. 78   26. 92  
price/book:  2. 54   3. 06   -1. 74  
operating margins:  0. 00 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  0. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  -13. 47 % --- ---
1-yr mean volatility:  -0. 10 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 18   2. 40   4. 10  
forward EPS:  -1. 31   3. 97   7. 13  
P/E:  -10. 30   13. 63   22. 72  
forward P/E:  -9. 24   -15. 95   13. 99  
PE/G:  1. 47   -1. 65   -1. 32  
growth:  -7. 00 % 127. 12 % 29. 61 %
earnings high:  -0. 30   1. 00   1. 66  
earnings avg:  -0. 34   0. 77   1. 53  
earnings low:  -0. 38   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -18. 75 % -2. 75 % 4. 55 %
return on equity:  -29. 69 % -18. 45 % 5. 46 %

beta (1yr vs S&P500):  1. 63   1. 25   0. 93  
sharpe (1yr):  -0. 47   0. 37   0. 70  

held % insiders:  1. 31 % 6. 39 % 3. 38 %
held % institutions:  106. 17 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : GLYC
.    + 2.304 =         2.304 :: INITIAL WEIGHT
.    + 81.27 =        83.574 :: inverse volume-to-price addition
.   + 47.213 =       130.787 :: spline projection addition
.    x 3.986 =       521.344 :: 13 weeks' performance factor
.    x 0.814 =       424.551 :: one-year gains+dividend factor
.    x 1.431 =       607.713 :: industry recommendation factor
.    x 2.565 =      1558.843 :: symbol recommendation factor
.    x 0.998 =      1555.921 :: return on assets factor
.    x 0.997 =      1551.301 :: return on equity factor
.    x 4.223 =      6551.521 :: current ratio factor
.    x 1.022 =      6692.418 :: quick ratio factor
.    x 1.021 =       6833.09 :: short ratio factor
.    x 2.025 =     13840.021 :: price-to-book factor
.    x 1.006 =      13916.89 :: 5-day avg > 50-day avg
.    x 1.973 =     27451.741 :: P/E weight
.    x 0.908 =     24927.632 :: PE/G factor
.    x 1.465 =     36509.343 :: beta factor
.    x 0.471 =     17198.536 :: sharpe factor
.    x 1.815 =     31223.226 :: target low factor
.     x 1.33 =     41535.997 :: target mean factor
.    x 1.137 =     47246.515 :: target high factor
.     x 1.31 =     61887.638 :: industry 2-weeks return factor
.    x 0.946 =     58516.496 :: "drift" penalty 4 days ago
.    x 0.996 =     58270.214 :: overall "drift" factor
.    x 0.999 =     58237.362 :: largest single-day jump factor
.    x 0.197 =     11486.658 :: low price factor
.      x 1.0 =     11484.794 :: factor hist industry gain for week 16
.   cubeRoot =        22.562 :: reduced to standardize
.   - 20.372 =          2.19 :: add/subtract for performance
.                       2.19 :: FINAL WEIGHT for NASDAQ:GLYC


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org